Home > Healthcare > Pharmaceuticals > Finished Drug Form > Carglumic Acid Market

Carglumic Acid Market Trends

Report ID: GMI8505
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Carglumic Acid Market Trends

The rise in awareness coupled with surging research and development (R&D) activities by key industry players is crucial in addressing metabolic diseases. Industry organizations are actively involved in the development of treatments and solutions for metabolic disorders.

The manufacturing key industry players have been actively engaged in surging research and development (R&D) activities to advance treatments and solutions for metabolic disorders. For instance, Eton Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. commercially launched Carglumic Acid tablets in December 2021, marking the first USFDA-approved generic version of this medication. Such activities are increasing the awareness of carglumic acid treatment among people and ultimately propelling their demand.
Additionally, Recordati Rare Diseases Inc. received approval from the U.S. FDA for a new indication of CARBAGLU (carglumic acid) tablets 200mg as adjunctive therapy in January 2021. These initiatives highlight the commitment of industry leaders to drive innovation and improve therapeutic options for individuals affected by metabolic disorders like N-acetylglutamate Synthase (NAGS) Syndrome and anticipates propelling the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global carglumic acid industry was valued at around USD 148.6 million in 2023 and is expected to reach around USD 280 million by 2032 at a CAGR of 7.1%, driven by the growing prevalence of metabolic diseases.

The hospital pharmacies segment accounted for a revenue of around USD 77 million in 2023, as they handle the distribution of medications for complex conditions such as hyperammonemia, ensuring that patients receive the necessary treatment.

North America carglumic acid market accounted for USD 60.4 million in 2023, attributed to the rising healthcare expenditure in the region, associated with a growing emphasis on specialty care and rare diseases treatment.

Apothecon Pharmaceuticals Pvt. Ltd., Biophore India Pharmaceuticals Pvt Ltd., Dipharma Francis S.r.l., Eton Pharmaceuticals, KAVYA PHARMA, MANUS AKTTEVA BIOPHARMA LLP, Merck KGaA, NOVITIUM PHARMA LLC, NURAY CHEMICALS, Recordati Rare Diseases Inc., and Suven Life Sciences Limited.